a b s t r a c t a r t i c l e i n f o
Rapamycin, an inhibitor of mammalian target of rapamycin (mTOR), is used in treatments for transplantation and cancer. Rapamycin causes hypomagnesemia, although precisely how has not been examined. Here, we investigated the effect of rapamycin on the expression of transient receptor potential melastatin 6 (TRPM6), a Mg 2+ channel. Rapamycin and LY-294002, an inhibitor of phosphatidilinositol-3 kinase (PI3K) located upstream of mTOR, inhibited epidermal growth factor (EGF)-induced expression of the TRPM6 protein without affecting TRPM7 expression in rat renal NRK-52E epithelial cells. Both rapamycin and LY-294002 decreased EGF-induced Mg 2+ influx. U0126, a MEK inhibitor, inhibited EGF-induced increases in c-Fos, p-ERK,
and TRPM6 levels. In contrast, neither rapamycin nor LY-294002 inhibited EGF-induced increases in p-ERK and c-Fos levels. EGF increased p-Akt level, an effect inhibited by LY-294002 and 1L-6-hydroxymethyl-chiro-inositol2-[(R)-2-O-methyl-3-O-octadecylcarbonate] (Akt inhibitor).
Akt inhibitor decreased TRPM6 level similar to rapamycin and LY-294002. These results suggest that a PI3K/Akt/mTOR pathway is involved in the regulation of TRPM6 expression. Rapamycin inhibited the EGF-induced increase in TRPM6 mRNA but did not inhibit human TRPM6 promoter activity. In the presence of actinomycin D, a transcriptional inhibitor, rapamycin accelerated the decrease in TRPM6 mRNA. Rapamycin decreased the expression and activity of a luciferase linked with the 3′-untranslated region of human TRPM6 mRNA. These results suggest that TRPM6 expression is upregulated by a PI3K/Akt/mTOR pathway and rapamycin reduces TRPM6 mRNA stability, resulting in a decrease in the reabsorption of Mg 2+ .
Introduction
Mammalian target of rapamycin (mTOR) plays a key role in the intracellular signaling pathways involved in cell growth and proliferation. Rapamycin, a specific inhibitor of mTOR, was initially developed as an immunosuppressant [1] . mTOR is a downstream effector of a phosphatidylinositol-3-kinase (PI3K)/Akt pathway. Hyperactivation or overexpression of the mTOR transduction protooncogenes recognized as Ras, PI3K, Akt, S6K1, and eIF4E has been shown in various solid tumor malignancies [2] . Therefore, rapamycin is also used in the treatment of kidney transplant patients with Kaposi's sarcoma, relapsed malignant glioma, hepatocellular carcinoma, and cholangiocellular carcinoma. However, rapamycin causes side effects such as dyslipidemia, bone marrow suppression, and hypomagnesemia [3] . The disturbance of magnesium homeostasis can lead to nephropathy. To prevent or lessen nephropathy, it is important to clarify the mechanism by which rapamycin causes hypomagnesemia.
The transient receptor potential (TRP) channel superfamily is a diverse group of cation channels expressed in mammalian cells and plays important roles in a variety of physiological processes [4, 5] . The melastatin subfamily (TRPM) contains eight distinct members, TRPM1-TRPM8. TRPM1-5 and TRPM8 are non-selective cation channels, whereas TRPM6 and TRPM7 show high permeability to magnesium and calcium [6, 7] . In the kidney, TRPM6 mRNA and protein are expressed in the distal convoluted tubule (DCT) [8] . The DCT is the main site of active transcellular magnesium reabsorption along the nephron. Mutations in the TRPM6 gene have been identified in patients with hypomagnesemia with secondary hypocalcemia (HSH) [9, 10] . TRPM6 must play an important role in the control of magnesium homeostasis.
The non-genomic regulation of TRPM6 channel has been well investigated in enforced expression studies [11] . In contrast, little is known about how the gene expression of TRPM6 mRNA is regulated. In isolated recessive renal hypomagnesemia, a mutation in the epidermal growth factor (EGF) gene was identified [12] . Immunohistochemical and electrophysiological analyses show that the mutation leads to insufficient activation of TRPM6. The activation of the EGF receptor causes the activation of several signaling pathways involving ERK1/2, phosphatidylinositol 3-kinase (PI3K), and p38 MAP kinase. We recently reported that EGF increases the expression of TRPM6 mRNA and protein mediated by the activation of a MEK/ERK/ c-Fos pathway in rat renal epithelial NRK-52E cells [13] .
Cyclosporine A (CsA), another immunosuppressant, decreases TRPM6 expression mediated by a decrease in c-Fos expression [14] . However, it is unknown whether rapamycin affects TRPM6 expression. In the present study, we found that rapamycin inhibits the EGF-induced increase in TRPM6 expression without affecting TRPM7 expression in NRK-52E cells. Rapamycin did not inhibit the promoter activity of human TRPM6 (hTRPM6). However, it accelerated the decrease in TRPM6 mRNA in the presence of actinomycin D, a transcriptional inhibitor. Our findings indicate that rapamycin reduces TRPM6 expression mediated by a decrease in mRNA stability.
Materials and methods

Materials
EGF was obtained from ProSpec-Tany TechnoGene (Rehovot, Israel). LY-294002 and U0126 were from Sigma-Aldrich (Saint Louis, MO, USA). Rapamycin was from LC laboratories (Woburn, MA). Goat anti-β-actin, rabbit anti-p-Akt, and rabbit anti-p-ERK1/2 antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA). Rabbit anti-TRPM6 (CHAK2) antibody was from Abgent (San Diego, CA). Rabbit anti-Akt antibody was from Rockland Immunochemicals (Gilbertsville, PA). Rabbit anti-ERK1/2 antibody was from Cell Signaling Technology (Beverly, MA). Mag-fura 2/acetoxymethyl ester (AM) and Pluronic F-127 were from Molecular Probes (Eugene, OR). 1L-6-Hydroxymethyl-chiroinositol2-[(R)-2-O-methyl-3-O-octadecylcarbonate] (Akt inhibitor) was from BioVision (Mountain View, CA). All other reagents were of the highest grade of purity available.
Cell culture
NRK-52E cells (IFO50480), derived from normal rat renal tubules, were obtained from the Japanese Collection of Research Biosciences (Osaka, Japan) and grown in Dulbecco's modified Eagle's medium supplemented with 5% fetal calf serum (FCS, HyClone, Logan, UT, USA), 0.07 mg/ml penicillin G potassium, and 0.14 mg/ml streptomycin sulfate in a humidified atmosphere containing 5% CO 2 at 37°C. The cells were cultured for 24 h in the medium without FCS before experiments.
Preparation of cell lysate and Western blotting
Cells were scraped into cold PBS and precipitated by centrifugation at 3000×g for 2 min. They were then lysed in a RIPA buffer containing 150 mM NaCl, 0.5 mM EDTA, 1% Triton X-100, 50 mM Tris-HCl (pH 8.0), a protease inhibitor cocktail (Sigma-Aldrich), and 1 mM phenylmethylsulfonyl fluoride, and sonicated for 20 s. The aliquot containing the nuclear fraction was used as a total cell extract. After centrifugation at 6000×g for 5 min, the supernatant was used as a cell lysate. The total cell extract and cell lysate were solubilized in a sample buffer for SDS-polyacrylamide gel electrophoresis. Protein concentrations were measured using a protein assay kit (Bio-Rad Laboratories, Hercules, CA) with bovine serum albumin as the standard. SDS-polyacrylamide gel electrophoresis was carried out as described previously [15] . In brief, samples (30-60 μg) were applied to the SDS-polyacrylamide gel. Proteins were blotted onto a PVDF membrane and incubated with each primary antibody followed by a peroxidase-conjugated secondary antibody. Finally, the blots were stained with an ECL Western blotting kit from GE Healthcare Bio-Science or a LumiGLO Reagent and Peroxide from Cell Signaling Technology.
Quantitative real-time reverse-transcription PCR (RT-PCR)
Total RNA was isolated from cells using ISOGEN (Nippon gene, Tokyo, Japan) and oligo-dT-primed in the presence of an M-MLV Reverse Transcriptase (42°C for 60 min and heated at 99°C for 5 min). Quantitative real-time PCR was performed using SYBR Premix Ex Taq (Takara Bio, Tokyo, Japan). The reaction conditions were an initial 10-s denaturation at 95°C, followed by 40 cycles of amplification (5 s of denaturation at 94°C and 34 s of annealing and extension at 60°C). At the final dissociation stage, the reaction conditions were 15 s at 95°C, 60 s at 60°C, 15 s at 95°C, and 15 s at 60°C. The following primers were used: rat TRPM6, forward 5′-ACCACCTAAGGCAGATGCAA-3′ and reverse 5′-CAACTTCATTTGGGCTTCTTG-3′; rat β-actin, forward 5′-CCAACCGTGAAAAGATGACC-3′ and reverse 5′-CCAGAGGCATACAGG-GACAG-3′; human luciferase, forward 5′-GCTCAGCAAGGAGGTAGGTG-3′ and reverse 5′-CCGGGAGCTGCATGTGTCAGAGG-3′. The threshold cycle (ct) for each PCR product was calculated by the instrument software, and ct values obtained for TRPM6 were normalized by subtracting the ct values obtained for β-actin. The resulting Δct values were then used to calculate the relative change in mRNA expression as the ratio (R) of mRNA expression for drug treatment/control according to the equation, R =2
.
Measurement of the intracellular free Mg
] i was determined using a Mg
2+
-sensitive fluorescent dye, mag-fura 2, as described previously [15] . Cells grown on glass slides were loaded with mag-fura 2/AM at 37°C for 20 min and placed in a glass cuvette. [Mg 2+ ] i was calculated according to the formula of Grynkiewicz et al. [16] . After the addition of 1 mM MgCl 2 , the increase in [Mg 2+ ] i for 10 min was calculated.
Luciferase reporter assay
The promoter region of the hTRPM6 gene [NC_000009.11] was subcloned into the pGL4.10(luc2) vector (Promega) upstream of a luciferase reporter gene [17] . A Renilla construct, pRL-TK vector (Toyobo, Tokyo, Japan), was used for normalizing transfection efficiency. Cells were transfected with plasmid DNA using HilyMax (Dojindo Laboratories, Kumamoto, Japan). After 48 h of transfection, luciferase activity was assessed using the Dual-Glo Luciferase Assay System (Promega, Madison, WI). EGF, U0126, LY-294002, and rapamycin were added for the final 24 h before the luciferase assay. The luminescence of the Firefly and Renilla luciferase was measured with a Multilabel Counter 1420 ARVOsx (Perkin Elmer, Wellesley, MA). Relative promoter activity was represented as the fold-increase compared to the promoterless pGL4.10 vector.
3′-Rapid amplification of cDNA ends (3′-RACE)
The 3′-RACE analysis was performed using total RNA from human kidney (Clontech Laboratories, CA, USA) with a 5′/3′ RACE Kit, 2nd Generation (Roche Applied Science, Mannheim, Germany). DNA was amplified using the PCR-anchor primer (5′-GACCACGCGTATC-GATGTCGAC-3′) and a specific primer (5′-GAGACGGGTAGAAATTCCC-CAGAA-3′). The sequence analysis was consigned to Bio Matrix Research (Chiba, Japan). The RACE products showed that the transcripts terminated at a site 458 bp downstream of the stop codon (Supplementary figure 1) . The 3′-untranslated region (3′-UTR) was subcloned into the pGL4.23(luc2/minP) vector (Promega) downstream of a luciferase reporter gene (Fig. 6A) . The expression and activity of luciferase were assessed as described above.
Statistics
Results are presented as the mean ± SEM. Differences between groups were analyzed by one-way analysis of variance, and corrections for multiple comparison were made using Tukey's multiple comparison test. Comparisons between two groups were made using Student's t test. Significant differences were assumed at p b 0.05.
Results
Decrease in TRPM6 expression and magnesium influx by rapamycin and LY-294002
TRPM6 mRNA and protein are expressed in renal epithelial NRK-52E cells [14] . The activation of receptor tyrosine kinases such as the EGF receptor and platelet-derived growth factor receptor leads to the activation of MEK/ERK and PI3K/Akt pathways [18, 19] . We recently reported that EGF increases TRPM6 expression, which is inhibited by U0126. Here, we found that rapamycin and LY-294002 inhibit the EGF-induced increase in TRPM6 protein (Fig. 1A and B) . In contrast, these inhibitors did not affect the expression of TRPM7 (Fig. 1C) . Rapamycin and LY-294002 inhibited the EGF-induced elevation in [Mg 2+ ] i (Fig. 1D) . These results suggest a rapamycin-and LY-294002-sensitive pathway to be involved in the regulation of TRPM6 expression and magnesium influx.
No cross-talk between the MEK/ERK and PI3K/Akt pathways
We examined whether LY-294002 decreases TRPM6 expression mediated by the inhibition of a MEK/ERK pathway similar to U0126. EGF increased TRPM6 and c-Fos expression, and this effect was inhibited by U0126 ( Fig. 2A) . In contrast, rapamycin and LY-294002 decreased TRPM6 expression but did not affect c-Fos expression. EGF increased p-ERK1/2 levels, and the increase was inhibited by U0126, but not by rapamycin or LY-294002 (Fig. 2B) . Total ERK1/2 levels were unaffected by EGF, U0126, rapamycin, and LY-294002. These results suggest that rapamycin and LY-294002 decrease TRPM6 expression via a pathway that is independent of ERK1/2. EGF also increased p-Akt level, and the increase was inhibited by LY-294002, but not by U0126 (Fig. 3A) . Therefore, we examined the effect of Akt inhibitor on TRPM6 expression. Akt inhibitor decreased p-Akt and TRPM6 expression similar to LY-294002 (Fig. 3B) . These results indicate that a PI3K/Akt/ mTOR pathway is involved in the up-regulation of TRPM6 expression.
3.3. Decrease in TRPM6 mRNA by U0126, LY-294002, Akt inhibitor, and rapamycin
The effects of U0126, LY-294002, Akt inhibitor, and rapamycin on TRPM6 mRNA expression were determined by quantitative RT-PCR. EGF increased TRPM6 mRNA level about 2-fold, which was inhibited by U0126, LY-294002, Akt inhibitor, and rapamycin (Fig. 4) . β-Actin mRNA was unaffected by these drugs. These results raise the possibility that the inhibition of a MEK/ERK pathway or a PI3K/Akt/ mTOR pathway reduces the transcriptional activity of TRPM6.
Decrease in stability of TRPM6 mRNA by rapamycin
The effects of U0126 and rapamycin on hTRPM6 promoter activity were examined using the hTRPM6-pGL4.10 vector. U0126 significantly inhibited the EGF-induced luciferase activity, whereas rapamycin did not (Fig. 5A ). The regulation of mRNA turnover is a crucial mechanism in the post-transcriptional control of gene expression [20] . To examine the stability of TRPM6 mRNA, we investigated the TRPM6 mRNA level in the presence of actinomycin D, a transcriptional inhibitor. NRK-52E cells were treated with rapamycin in the presence of EGF and actinomycin D for 0, 3, 6, and 9 h. The TRPM6 mRNA level decreased in a timedependent manner (Fig. 5B) . Rapamycin accelerated the decrease, indicating that it reduces the stability of the mRNA. In contrast, U0126 did not significantly change the rate of decrease in TRPM6 mRNA (Fig. 5C ). Furthermore, U0126 did not enhance the effect of rapamycin on the decrease in TRPM6 mRNA. These results indicate that U0126 does not affect the stability of TRPM6 mRNA.
Effect of 3′-UTR on the expression and stability of luciferase
We examined the effect of the 3′-UTR of hTRPM6 on the stability of the luc2 reporter gene. 3′-RACE showed that hTRPM6 mRNA contains a 458-bp 3′-UTR (Supplementary figure 1) . As shown in Fig. 6A , the 3′-UTR of hTRPM6 was inserted into the pGL4.23 vector between the luc2 and SV40 late poly (A) signal sequences. EGF did not affect the mRNA expression or activity of the luciferase-linked with the 3′-UTR of hTRPM6, whereas rapamycin significantly decreased both (Fig. 6B  and C) . Neither EGF nor rapamycin affected the expression or activity of the luciferase in the mock-transfected cells. These results suggest that the 3′-UTR of TRPM6 is involved in stabilizing the mRNA and the stability is decreased by rapamycin. Fig. 4 . Decrease in TRPM6 mRNA caused by U0126 and inhibitors of the PI3K/Akt/mTOR pathway. (A) Cells were pre-incubated with 25 μM U0126, 25 μM LY-294 002, 10 μM Akt inhibitor, or 5 μM rapamycin for 30 min before the addition of EGF. They were then incubated with 10 ng/ml EGF plus U0126, LY-294002, Akt inhibitor, or rapamycin for 24 h. After the isolation of total RNA from the cells, quantitative RT-PCR was performed using specific primers for rat TRPM6 and β-actin. The rat TRPM6 mRNA level was normalized to the β-actin level and expressed as the fold-increase over the control value. Data represent the mean ± SEM for four experiments. **P b 0.01 compared with control.
## P b 0.01 compared with EGF.
Discussion
The hypomagnesemia commonly observed in FK506-or cyclosporine A (CsA)-treated patients has been implicated in nephropathy.
Rapamycin has structural similarities with FK506 but suppresses the immune system via different mechanisms [21] . Rapamycin also causes hypomagnesemia similar to FK506 and CsA. These immunosuppressants may inhibit renal reabsorption of Mg 2+ because they increase the urinary excretion of Mg
2+
. Approximately 80% of the total concentration of Mg 2+ in plasma is filtrated in the glomeruli, and the majority is subsequently reabsorbed along the nephron. TRPM6 is distributed in the DCT, which reabsorbs 5-10% of the filtered Mg 2+ , and the reabsorption in this segment defines the final urinary Mg 2+ concentration. Therefore, a dysfunctional TRPM6 causes hypomagnesemia [9] . We recently found that CsA reduces TRPM6 expression via a decrease in c-Fos expression [14] . In contrast, the effect of rapamycin on TRPM6 expression has not been examined.
Little is known about the regulatory mechanism of TRPM6 expression. In mice, TRPM6 expression is up-regulated in the kidney and colon by 17β-estradiol and a magnesium-enriched diet, respectively [22] . We reported that the EGF-dependent activation of a MEK/ ERK/c-Fos pathway is involved in the up-regulation of TRPM6 expression in NRK-52E cells [13, 17] . Signaling by EGF-like ligands is transduced into cytoplasmic signaling pathways such as the MEK/ After the isolation of total RNA from the cells, quantitative RT-PCR was performed using specific primers for rat TRPM6 and β-actin. The rat TRPM6 mRNA level was normalized to the β-actin level and expressed as the fold-decrease compared to 0 h. (C) Cells were preincubated in the absence and presence of 25 μM U0126, 5 μM rapamycin, or U0126 plus rapamycin for 30 min. They were then incubated with 10 μM actinomycin D plus 10 ng/ml EGF in the absence and presence of these inhibitors for 9 h. Data represent the mean± SEM for four experiments. **P b 0.01 compared with control. ERK, p38 MAP kinase, JNK, and PI3K pathways. Inhibitors of p38 MAP kinase and JNK did not affect TRPM6 expression [14] . In the present study, we found that rapamycin decreases the expression of TRPM6 mRNA and protein.
Several studies show that PI3K inhibitors block the phosphorylation of ERK1/2 caused by stimuli such as insulin, PDGF, and EGF [23] [24] [25] , suggesting that ERK1/2 are downstream effectors of PI3K signaling. In contrast, PI3K does not have any effect on the EGFinduced phosphorylation of ERK1/2 [26] . In NRK-52E cells, EGF increased p-ERK1/2 and p-Akt levels, effects that were inhibited by U0126 and LY-294002, respectively (Figs. 2 and 3) . These results suggest that there is no crosstalk between the MEK/ERK and PI3K/ Akt/mTOR pathways. Akt, a downstream target of PI3K, is responsible for many of the biological consequences of PI3K activation [27] . Akt inhibitor blocked the EGF-induced elevation in p-Akt and TRPM6 levels (Figs. 3 and 4) . We suggest that TRPM6 expression is up-regulated by a PI3K/Akt/mTOR pathway.
The mTOR serine/threonine kinase is the catalytic subunit of two functionally distinct protein complexes, mTORC1 and mTORC2 [28] . mTORC1 containing Raptor, mLST8/GβL, and PRAS is sensitive to rapamycin. In contrast, mTORC2 containing Rictor, mLST8/GβL, Sin1, and Protor is resistant to rapamycin. The EGF-induced increase in TRPM6 expression was inhibited by rapamycin in NRK-52E cells (Fig. 1) , suggesting that TRPM6 expression is regulated by mTROC1. However, Sarbassov et al. [29] reported that mTORC2 is sensitive to prolonged rapamycin treatment (for 24 h). We cannot exclude the possibility that mTROC2 is involved in the regulation of TRPM6 expression, but we suggest that TRPM6 expression is regulated by mTORC1 because rapamycin accelerated the decrease in TRPM6 mRNA within 3 h (Fig. 5B) .
The TRPM6 mRNA level was decreased by U0126, LY-294002, Akt inhibitor, and rapamycin in NRK-52E cells (Fig. 4) , suggesting the transcriptional activity of TRPM6 to be inhibited by these drugs. However, the luciferase reporter assay showed that U0126 inhibits TRPM6 promoter activity, whereas rapamycin does not (Fig. 5A) . So far, it has been reported that LY-294002 decreases the stability of α1 collagen type I mRNA [30] , cyclin D1 mRNA [31] , and formyl peptide receptor 1 mRNA [32] . It should be noted that rapamycin accelerated the decrease in TRPM6 mRNA in the presence of actinomycin D (Fig. 5B and C) , suggesting that it reduces the stability of TRPM6 mRNA. The most described RNA element involved in the stability of short-lived messages is the AU-rich elements (AREs) within the 3′-UTR [33] . The ARE-containing sequence decreased cyclooxygenase-2 mRNA level in human ovarian cancer cells [34] and cytokines mRNA levels in HeLa-tTA cells [35] . The 3′-UTR of TRPM6 contains AU-rich region, but the motif is not fitted with the classical motifs. However, rapamycin decreased the expression and activity of the luciferase linked with the 3′-UTR of hTRPM6 (Fig. 6) . The removal of the 5′-cap (decapping) permits degradation of mRNA. The decapping activity is inhibited by the cap-binding protein eIF4E located downstream of mTOR [36] . We suggest that rapamycin affects the 3′-UTR of TRPM6 and decreases the stability of the mRNA. Further study is needed to clarify how rapamycin reduces the stability of TRPM6 mRNA.
In conclusion, TRPM6 expression is regulated by two signaling pathways, MEK/ERK and PI3K/Akt/mTOR (Fig. 7) . U0126 decreases TRPM6 expression by reducing transcriptional activity [17] . In contrast, rapamycin inhibited the EGF-induced increase in TRPM6 expression and [Mg 2+ ] i by reducing the stability of TRPM6 mRNA. We suggest that a PI3K/Akt/mTOR pathway is involved in regulating the stability of TRPM6 mRNA. Rapamycin causes hypomagnesemia with high urinary excretion of magnesium in rats [3] . The decrease in the stability of TRPM6 mRNA caused by rapamycin may inhibit the reabsorption of Mg 2+ in the kidneys, resulting in hypomagnesemia.
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